Prime Medicine, Inc. Increase (Decrease) in Accounts Receivable
Prime Medicine, Inc. (PRME) reported Increase (Decrease) in Accounts Receivable of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- Prime Medicine, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$120.00K, a 100.22% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was $103.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | -$120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$17.00K derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-07 |
| 2025-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $120.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $17.00K 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | $55.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $55.00M derived: sum of 2 quarters · filed 2025-11-07 | $55.00M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |